TAIZHOU, China, July 3, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced that it has begun the production of TCM Homologous Supplements ("TCMHS"), a classification of health-supporting food used traditionally in China as TCM but which are also consumed as food.
The Company recently reconstructed and assembled an 850-square-meter facility and received a "Food Manufacturing Certificate" issued by the local Food and Drug Administration, which granted the Company permission to produce TCMHS. The scope of production includes "Substitute Teas," made of TCMHS plants, and "Solid Beverages," a kind of granule produced through extraction of TCMHS materials.
The Company has successfully developed 42 substitute tea and 4 solid beverage products. The 4 solid beverage products were commercially launched in April 2019, and the commercial launch for the 42 substitute tea products is scheduled for October 2019.
Mr. Feng Zhou, Chief Executive Officer and Director of China SXT, commented, "We are excited about our strategic expansion into the 'Big Health' industry being promoted by the Chinese government. Through introducing the new TCMHS products, we will expand our customer base and promote our brand. By supplementing our core TCMP product line, we will fuel sustainable growth for our shareholders in the years to come."
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company's statements regarding the closing of the proposed private placement are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; the growth of the pharmaceutical market, particularly the Traditional Chinese Medicine Pieces ("TCMPs") market, in China; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company serves and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward – looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
At the Company:
Alex Shi, CFO
Email: alexyaoshi@qq.com
ICR, LLC
Rose Zu
Email: ir@sxtchina.com
Phone: +1-646-277-1287
View original content:http://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-announces-tcm-homologous-supplements-production-300879744.html
